HTA Programme - New Projects and Publications

Project: Treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

Chief Investigator: Dr Emma Loveman, Senior Research Fellow, Southampton Health Technology Assessments Centre, University of Southampton
Research Type: Secondary Research (e.g. systematic review)
ICD Chapters: Respiratory diseases
Key Areas: NOT APPLICABLE
Interventions: Respiratory medicine
ICD Diseases: NOT APPLICABLE
Research Type: Secondary Research (e.g. systematic review)
Expected publication date: Mid 2014
HTA project ref: 10/50/06

Project: Development of a cost-effectiveness model for optimization of the screening interval in diabetic retinopathy screening.

Chief Investigator: Dr Henry (Peter) Scanlon, Consultant Ophthalmology, Ophthalmology, Gloucestershire Hospitals NHS Foundation Trust
Research Type: Primary Research (e.g. trial)
ICD Chapters: Endocrine, nutritional and metabolic diseases, Eye diseases
Key Areas:
ICD Diseases: Diabetes
Research Type: Primary Research (e.g. trial)
Expected publication date: Mid 2015
HTA project ref: 10/66/01

Project: Non pharmacological interventions for Attention-Deficit/Hyperactivity Disorder (ADHD) delivered in school settings: a systematic review of quantitative and qualitative research

Chief Investigator: Dr Tamsin Ford, Senior Clinical Lecturer, Institute of Health Services Research, Peninsula Medical School, University of Exeter
Research Type: Secondary Research (e.g. systematic review)
ICD Chapters: Mental illness
Key Areas: Children, Mental Health
ICD Diseases: NOT APPLICABLE
Research Type: Secondary Research (e.g. systematic review)
Expected publication date: Late 2014
HTA project ref: 10/140/02

Publication: Volume 16, number 23 (Loveman). Report identifies limited new information on the clinical effectiveness of dasatinib, nilotinib and high-dose imatinib for the treatment of people with chronic myeloid leukaemia (CML) who are resistant to standard-dose imatinib, but suggests that the interventions can lead to improvements in haematological and cytogenetic responses in people with imatinib-resistant CML.

Chief Investigator: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Research Type: NICE Technology Assessment Report (TAR)
ICD Chapters: Cancers
Key Areas: Cancer
Interventions: Medical oncology
ICD Diseases: Leukaemia
Research Type: NICE Technology Assessment Report (TAR)
Publication date: 08/05/2012
HTA project ref: 09/90/01

Publication: Volume 16, number 22 (Rogers). Study found dasatinib and nilotinib appear efficacious in terms of obtaining cytogenetic and haematological responses in both imatinib-resistant and imatinib-intolerant populations.

Chief Investigator: Peninsula Medical School (PenTAG), University of Exeter
Research Type: NICE Technology Assessment Report (TAR)
ICD Chapters: Cancers
Key Areas: Cancer
ICD Diseases: Leukaemia
Research Type: NICE Technology Assessment Report (TAR)
Publication date: 08/05/2012
HTA project ref: 08/31/01